Galapagos announces fda clearance of ind application for phase 1/2 atalanta-1 study of cd19 car-t, glpg5101, in relapsed/refractory non-hodgkin lymphoma

Mechelen, belgium; august 23, 2024, 07:00 cet; regulated information – inside information – galapagos nv (euronext & nasdaq: glpg) today announced that the u.s. food and drug administration (fda) has cleared galapagos' investigational new drug (ind) application for atalanta-1, a phase 1/2 multicenter study evaluating the feasibility, safety, and efficacy of glpg5101 in patients with relapsed/refractory non-hodgkin lymphoma (r/r nhl).
CAR Ratings Summary
CAR Quant Ranking